RFI deadline is June 2, 2025
Host a NIIMBL eXperience in 2026.
Application Deadline: July 10, 2025
Application Deadline: July 7, 2025
Collaborate on innovative manufacturing platforms and technologies that accelerate the development and manufacture of life-saving medicines and medical countermeasures, enhance national economic security, and support response to biothreats
Help companies de-risk the adoption and implementation of new technologies and approaches for development and manufacturing
Strengthen the U.S. economy by cultivating a world-leading biopharmaceutical workforce that meets the industry’s needs through novel training and education programs
Udit Batra, President & CEO, Waters
We achieve our mission through an RFx process that aims to advance technical and workforce development projects:
The NIIMBL eXperience Program RFA seeks applications from member academic or non-profit organizations interested in hosting a cohort of first- and second-year college students for a week-long eXperience program during the summer of 2026.
NIIMBL intends to award up to five locations with a maximum budget of $100,000.
The application deadline is July 10, 2025.
NIIMBL is seeking input and interest in the concept of NIIMBL eXperience Day, an effort to raise awareness of the biopharmaceutical industry for all education levels and backgrounds. NIIMBL eXperience Day will build on the success of the week-long eXperience program. Similar to the eXperience program, NIIMBL eXperience Day should include hands-on activities, industry partners, and interactions with professionals working in biopharmaceutical manufacturing, but will focus specifically on local/regional audiences.
The submission deadline is June 2, 2025.
Interoperable Model Module to Simulate Scale-Dependent Effects during Cell Culture Production of Glycosylated Proteins Request for Application (RFA2025.01)
Objectives of the project: Develop software modules which are interoperable with others developed for the NIIMBL Big Data Program modeling and simulation team for protein glycosylation prediction. The newly developed modules will incorporate scale-dependent effects common in biopharmaceutical manufacturing and increase accuracy of cell culture process and protein glycosylation profile predictions for all scales.
Through this RFA, NIIMBL intends to fund one project with funding up to $300,000.
The application deadline is July 7, 2025.
Interoperable Model Module to Simulate Buffer-Induced pH-Shifts During Chromatography Steps Request for Application (RFA2025.02)
Objectives of the project: Develop software modules which are interoperable with others within the CADET Chromatography Analysis and Design Toolkit (https://cadet-web.de/simulation/about_us/). The resulting modules would increase accuracy of predictions for all chromatography separations which involve ionic interactions (CEX, AEX, Protein-A, Hydroxyapatite, etc.). The modules would also be applicable to many different wash and elution contexts (buffer, salts, adsorbed species, adsorbent ligand, etc.) through use of libraries of titratable group pK values and other parameters needed for the simulation. It is most desirable that modules use open-source tools which do not require special licenses or cost for their use (Python, etc.)
Through this RFA, NIIMBL intends to fund one project with funding up to $300,000.
The application deadline is July 7, 2025.
This Viral Vector Program Request for Applications (RFA) aims to fund a team to participate in its the Program’s initiative on optimizing long-read next generation sequencing (NGS) capabilities.
This RFA closed April 4, 2025.
NIIMBL is planning a special session at the 2025 National Meeting. The meeting is scheduled to be held in Washington DC from June 24-27, 2025. The special session will be a pitch session (i.e. “Shark Tank”-style) where three organizations will be invited to pitch their promising technology in front of a panel of experts. Each of the three organizations will be given 30 minutes total time consisting of a short introductory statement followed by panel question and answer. At the end of the session, a process will be used to select a winning pitch. Because only three organizations will be given an opportunity to present, this RFI is being used to help identify interested parties. The primary intended and expected type of organization would be small companies (e.g. Tier 3 industry members) with promising biopharmaceutical manufacturing-related technology. However, an academic member planning to pursue commercialization of a new technology or a large company with a promising new technology are welcome to submit information but may not be prioritized over small businesses.
Purpose of this RFI:
This RFI closed April 7, 2025.
RFP 8.1 includes global health, technology development, and workforce development topics. It is open to current NIIMBL members and to new members by the close of the full proposal deadline.
Project Call 8.1 closed on September 30, 2024.
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
The NIIMBL Faculty Fellows program closes December 31, 2024.
We achieve our mission through an RFx process that aims to advance technical and workforce development projects:
2026 NIIMBL eXperience RFA
The NIIMBL eXperience Program RFA seeks applications from member academic or non-profit organizations interested in hosting a cohort of first- and second-year college students for a week-long eXperience program during the summer of 2026.
NIIMBL intends to award up to five locations with a maximum budget of $100,000.
The application deadline is July 10, 2025.
NIIMBL eXperience Day RFI
NIIMBL is seeking input and interest in the concept of NIIMBL eXperience Day, an effort to raise awareness of the biopharmaceutical industry for all education levels and backgrounds. NIIMBL eXperience Day will build on the success of the week-long eXperience program. Similar to the eXperience program, NIIMBL eXperience Day should include hands-on activities, industry partners, and interactions with professionals working in biopharmaceutical manufacturing, but will focus specifically on local/regional audiences.
The submission deadline is June 2, 2025.
Big Data Interoperable Module (Upstream) RFA2025.01
Interoperable Model Module to Simulate Scale-Dependent Effects during Cell Culture Production of Glycosylated Proteins Request for Application (RFA2025.01)
Objectives of the project: Develop software modules which are interoperable with others developed for the NIIMBL Big Data Program modeling and simulation team for protein glycosylation prediction. The newly developed modules will incorporate scale-dependent effects common in biopharmaceutical manufacturing and increase accuracy of cell culture process and protein glycosylation profile predictions for all scales.
Through this RFA, NIIMBL intends to fund one project with funding up to $300,000.
The application deadline is July 7, 2025.
Big Data Interoperable Module (Downstream) RFA2025.02
Interoperable Model Module to Simulate Buffer-Induced pH-Shifts During Chromatography Steps Request for Application (RFA2025.02)
Objectives of the project: Develop software modules which are interoperable with others within the CADET Chromatography Analysis and Design Toolkit (https://cadet-web.de/simulation/about_us/). The resulting modules would increase accuracy of predictions for all chromatography separations which involve ionic interactions (CEX, AEX, Protein-A, Hydroxyapatite, etc.). The modules would also be applicable to many different wash and elution contexts (buffer, salts, adsorbed species, adsorbent ligand, etc.) through use of libraries of titratable group pK values and other parameters needed for the simulation. It is most desirable that modules use open-source tools which do not require special licenses or cost for their use (Python, etc.)
Through this RFA, NIIMBL intends to fund one project with funding up to $300,000.
The application deadline is July 7, 2025.
Viral Vector RFA2025.1
This Viral Vector Program Request for Applications (RFA) aims to fund a team to participate in its the Program’s initiative on optimizing long-read next generation sequencing (NGS) capabilities.
This RFA closed April 4, 2025.
RFI 2025.1: "Shark Tank" Pitches National Meeting
NIIMBL is planning a special session at the 2025 National Meeting. The meeting is scheduled to be held in Washington DC from June 24-27, 2025. The special session will be a pitch session (i.e. “Shark Tank”-style) where three organizations will be invited to pitch their promising technology in front of a panel of experts. Each of the three organizations will be given 30 minutes total time consisting of a short introductory statement followed by panel question and answer. At the end of the session, a process will be used to select a winning pitch. Because only three organizations will be given an opportunity to present, this RFI is being used to help identify interested parties. The primary intended and expected type of organization would be small companies (e.g. Tier 3 industry members) with promising biopharmaceutical manufacturing-related technology. However, an academic member planning to pursue commercialization of a new technology or a large company with a promising new technology are welcome to submit information but may not be prioritized over small businesses.
Purpose of this RFI:
This RFI closed April 7, 2025.
RFP 8.1
RFP 8.1 includes global health, technology development, and workforce development topics. It is open to current NIIMBL members and to new members by the close of the full proposal deadline.
Project Call 8.1 closed on September 30, 2024.
RFA: Faculty Fellows
NIIMBL is pleased to announce the pilot of a faculty sabbatical in industry program. The NIIMBL Faculty Fellows program provides financial support for faculty or instructional staff at universities and community colleges to pursue a sabbatical either at an industry member (Tier 1 or Tier 2) or at NIIMBL’s Headquarters (NIIMBL HQ) in Delaware to support NIIMBL-led projects.
The NIIMBL Faculty Fellows program closes December 31, 2024.
Our members are stakeholders from across the biopharmaceutical manufacturing ecosystem, including large and small companies, academic institutions, and nonprofits.
Members have the opportunity to collectively revolutionize current biomanufacturing platforms, processes, and educational programs and share in the benefits of these transformative solutions.
The NIIMBL ecosystem’s collaborative efforts to accelerate innovative manufacturing technologies help to:
Biopharmaceuticals are medicines and medical countermeasures that save, sustain, and improve lives. They:
Mike Kress, Sr. Vice President Development Sciences and Clinical Supply,
Merck & Co., Inc.
We offer a variety of membership options that give you the flexibility to choose your organization’s level of engagement based on technology interests and priorities.
